Health Advances LLC, Newton, MA 02466, USA.
Future Oncol. 2020 Dec;16(36):3061-3074. doi: 10.2217/fon-2020-0648. Epub 2020 Sep 9.
Prior studies have established that broader incorporation of active surveillance, guided by additional prognostic tools, may mitigate the growing economic burden of localized prostate cancer in the USA. This study sought to further explore the potential of a particular gene expression-based prognostic tool to address this unmet need. A deterministic, decision-analytic model was developed to estimate the economic impact of the Prolaris test on a US commercial health plan. When adopted in patients classified by the American Urological Association as low or intermediate risk, the assay was projected to reduce costs by $1894 and $2129 per patient over 3 and 10 years, respectively, largely through the increased use of active surveillance.
先前的研究已经证实，通过更多的预后工具来更广泛地采用主动监测，可能会减轻美国局限性前列腺癌不断增长的经济负担。本研究旨在进一步探讨一种特定的基于基因表达的预后工具来满足这一未满足的需求。采用确定性决策分析模型来估算美国商业健康计划中 Prolaris 检测的经济影响。当在美国泌尿外科学会（American Urological Association）低风险或中风险的患者中采用时，该检测在 3 年和 10 年内分别预计可使每位患者的成本降低 1894 美元和 2129 美元，主要是通过增加主动监测的使用。
